SEER$1.72
$1.75
Chart
Performance
Key Stats
AI SEER Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralSeer, Inc. shows a mixed investment profile. While its core business addresses a growing market, recent performance and technical indicators suggest a neutral stance. Investors should monitor upcoming earnings and industry trends.
Thematic
Seer operates in the life sciences and proteomics sector, which has strong long-term growth potential driven by advancements in biological research and diagnostics. However, the company's current focus on research use only products may limit its immediate market penetration.
Fundamental
Seer's financials indicate significant losses and negative profitability, with a considerable cash burn. While it maintains a healthy cash position, revenue has been modest and inconsistent.
Technical
Seer's stock price has seen recent volatility, trading within a range. Key technical indicators suggest a neutral short-term outlook, with some indicators pointing towards potential upside if key resistance levels are breached.
| Factor | Score |
|---|---|
| Proteomics Market Growth | 85 |
| Life Sciences Innovation | 70 |
| Biopharmaceutical & Biotech Demand | 70 |
| Regulatory Landscape (Non-Diagnostic) | 75 |
| Geographic Reach | 75 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 80 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Volume Confirmation | 65 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Earnings Surprise
Seer, Inc. has a history of beating earnings estimates. For instance, in Q2 2025, the reported EPS of -0.31 exceeded the estimate of -0.36 by 14.68%.
Negative P/E Ratio Suggesting Growth Potential
The Price-to-Earnings (P/E) ratio is currently negative (-2.1 TTM, -1.5 for 2024, -1.4 for 2023), which is common for growth-oriented companies that are reinvesting heavily. This suggests potential for future earnings growth if their strategy is successful.
Bearish Points (8)
Consistent Net Losses
Seer, Inc. has consistently reported net losses, with the TTM net income at -$63.02 million and annual net income for 2024 at -$86.60 million. This indicates the company is not currently profitable.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is significantly high, at 10.8 TTM and 9.1 for 2024. This suggests the market values the company's revenue much higher than its current earnings, implying high growth expectations.
Calendar
August 2025
7
Next Earnings Date
H: $-0.35
A: $-0.37
L: $-0.39
H: 4.00M
A: 3.75M
L: 3.50M
Profile
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in the field of proteomics, offering a platform for protein measurement at scale, though using different technology (aptamer-based vs. Seer's mass spectrometry). Both aim to provide deep insights into the proteome for biomarker discovery and drug development.
Weight: 97
Direct competitor in the field of targeted proteomics, utilizing proximity extension assay (PEA) technology for high-throughput protein analysis. Olink and Seer target similar applications in clinical research and biomarker discovery.
Weight: 95
A global leader in life science tools and a major manufacturer of mass spectrometry instruments, which are foundational to proteomics. Thermo Fisher is a potential partner, supplier, or competitor across various life science research areas.
Weight: 92
Competitor in high-sensitivity protein detection, primarily for biomarker discovery, using their Simoa technology. Their focus on ultra-low abundance proteins and multiplexing overlaps with Seer's high-sensitivity aspirations and market applications.